MCID: HTL001
MIFTS: 37

Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

MalaCards integrated aliases for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis:

Name: Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis 20
Human T-Cell Leukemia Virus Type 1 Associated Myelopathy/tropical Spastic Paraparesis 20
Tropical Spastic Paraparesis 70
Ham/tsp 20

Classifications:



External Ids:

UMLS 70 C0030481

Summaries for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

GARD : 20 HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive disease of the nervous system that affects less than 2% of people with HTLV-1 infection. Signs and symptoms vary but may include slowly progressive weakness and spasticity of one or both legs, exaggerated reflexes, muscle contractions in the ankle, and lower back pain. Other features may include urinary incontinence and minor sensory changes, especially burning or prickling sensations and loss of vibration sense. The reason some people with HTLV-1 infection develop HAM/TSTP is not well understood. Treatment generally aims to control the specific symptoms, as there is no standard treatment available. Interferon alpha may be beneficial over short periods, and some aspects of the disease may be improved with interferon beta. Other medications may include i mmune globulin, oral corticosteroids, and muscle relaxers such as baclofen or tizanidine.

MalaCards based summary : Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis, also known as human t-cell leukemia virus type 1 associated myelopathy/tropical spastic paraparesis, is related to tropical spastic paraparesis and spastic paraparesis. An important gene associated with Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis is HLA-A (Major Histocompatibility Complex, Class I, A), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Cytokine Signaling in Immune system. The drugs Pentoxifylline and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Diseases related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 tropical spastic paraparesis 32.5 IFNL3 HLA-B HLA-A
2 spastic paraparesis 31.9 IFNL3 HLA-B HLA-A
3 herpes zoster 30.0 HLA-DRB1 HLA-B HLA-A
4 mumps 30.0 HLA-DRB1 HLA-DQB1
5 multiple sclerosis 29.8 VDR HLA-DRB1 HLA-DQB1 HLA-A
6 psoriasis 29.6 VDR HLA-DRB1 HLA-B HLA-A
7 primary progressive multiple sclerosis 29.6 HLA-DRB1 HLA-DQB1
8 graft-versus-host disease 29.5 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
9 rubella 29.5 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
10 alopecia areata 29.5 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
11 autoimmune disease 29.2 VDR HLA-DRB1 HLA-DQB1 HLA-B HLA-A
12 myelopathy, htlv-1-associated 12.0
13 human t-cell leukemia virus type 1 11.7
14 retrovirus-associated myelopathy 11.6
15 t-cell lymphoblastic leukemia/lymphoma 11.1
16 leukemia, t-cell, chronic 11.1
17 adult t-cell leukemia 11.0
18 t-cell adult acute lymphocytic leukemia 10.8
19 leukemia 10.7
20 spasticity 10.7
21 lymphoma 10.7
22 dermatitis 10.7
23 infective dermatitis associated with htlv-1 10.6
24 neurogenic bladder 10.5
25 syphilis 10.5
26 peripheral nervous system disease 10.5
27 neuropathy 10.5
28 chronic pain 10.5
29 myositis 10.3
30 schistosoma mansoni infection, susceptibility/ 10.3
31 3-methylglutaconic aciduria, type iii 10.3
32 human immunodeficiency virus type 1 10.3
33 sexual disorder 10.3
34 polymyositis 10.3
35 strongyloidiasis 10.3
36 sarcoma 10.3
37 low compliance bladder 10.3
38 uveitis 10.3
39 polyneuropathy 10.3
40 interstitial cystitis 10.3
41 schistosomiasis 10.3
42 prostatitis 10.3
43 cystitis 10.3
44 optic nerve disease 10.3
45 neuroaxonal dystrophy 10.3
46 cerebellar disease 10.3
47 myelitis 10.3
48 central nervous system disease 10.3
49 purpura 10.3
50 skin disease 10.3

Graphical network of the top 20 diseases related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis:



Diseases related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Symptoms & Phenotypes for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

GenomeRNAi Phenotypes related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.77 HLA-A HLA-B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.77 HLA-A HLA-B
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.77 HLA-A HLA-B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.77 HLA-A HLA-B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.77 HLA-A HLA-B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.77 HLA-A HLA-B
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.77 HLA-A HLA-B

Drugs & Therapeutics for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Drugs for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
4 Vasodilator Agents Phase 3
5 Phosphodiesterase Inhibitors Phase 3
6 Protective Agents Phase 3
7 Antioxidants Phase 3
8 Platelet Aggregation Inhibitors Phase 3
9 Radiation-Protective Agents Phase 3
10 Anti-Infective Agents Phase 2, Phase 3
11 Antirheumatic Agents Phase 2, Phase 3
12 Dermatologic Agents Phase 2, Phase 3
13 Immunosuppressive Agents Phase 2, Phase 3
14 Immunologic Factors Phase 2, Phase 3
15 Calcineurin Inhibitors Phase 2, Phase 3
16 Antifungal Agents Phase 2, Phase 3
17 Cyclosporins Phase 2, Phase 3
18
Infliximab Approved Phase 2 170277-31-3
19 Gastrointestinal Agents Phase 2
20 Immunoglobulins Phase 1
21 Antibodies Phase 1
22 Antibodies, Monoclonal Phase 1
23
Zidovudine Approved Early Phase 1 30516-87-1 35370
24
Valproic acid Approved, Investigational 99-66-1 3121
25 Raltegravir Potassium Early Phase 1
26 Anti-Retroviral Agents Early Phase 1
27 Anti-HIV Agents Early Phase 1
28 Antiviral Agents Early Phase 1
29 HIV Integrase Inhibitors Early Phase 1
30 Integrase Inhibitors Early Phase 1
31 Antimetabolites Early Phase 1
32 Reverse Transcriptase Inhibitors Early Phase 1
33 Psychotropic Drugs
34 Neurotransmitter Agents
35 Anticonvulsants

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
2 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
3 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
4 Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis Not yet recruiting NCT04799288 Phase 1, Phase 2 Teriflunomide
5 An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP Terminated NCT00823641 Phase 2 Infliximab
6 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
7 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
8 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
9 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
10 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
11 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
12 Therapeutic Effect of the Pilates Method in People With HAM/TSP: a Randomized Crossover Study Completed NCT04830319
13 Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP) Recruiting NCT00001778
14 Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP Terminated NCT00519181 Valproic Acid

Search NIH Clinical Center for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Genetic Tests for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Anatomical Context for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

MalaCards organs/tissues related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis:

40
T Cells, Spinal Cord, Bone, B Cells, Endothelial, Thymus, Monocytes

Publications for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Articles related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis:

(show top 50) (show all 1593)
# Title Authors PMID Year
1
Analysis of a within-host HIV/HTLV-I co-infection model with immunity. 61
33157165 2021
2
HTLV-1 oncovirus-host interactions: From entry to the manifestation of associated diseases. 61
33742509 2021
3
Anti-human T-cell leukemia virus type 1 (HTLV-1) antibody assays in cerebrospinal fluid for the diagnosis of HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
33658267 2021
4
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) versus adult T-cell leukemia/lymphoma (ATLL). 61
33757561 2021
5
Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population. 61
33649182 2021
6
A significant association between CXCL10 -1447 A > G and IL18 -607 C > A gene polymorphism with human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM-TSP), a case-control report from city of Mashhad, Iran. 61
33651323 2021
7
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. 61
32835825 2021
8
Immunopathogenic CSF TCR repertoire signatures in virus-associated neurologic disease. 61
33616082 2021
9
Extracellular vesicles from HTLV-1 infected cells modulate target cells and viral spread. 61
33622348 2021
10
Screening for Human T-Cell Lymphotropic Virus (HTLV) in Pregnant Women in the Peruvian Amazon and Systematic Review with Meta-Analysis of HTLV Infection in Peru. 61
33668710 2021
11
Human T-cell leukemia virus type 1 infection among Japanese immigrants and their descendants living in Southeast Brazil: A call for preventive and control responses. 61
33544713 2021
12
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. 61
32054656 2021
13
Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSP. 61
33632146 2021
14
Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. 61
33767694 2021
15
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. 61
33423163 2021
16
Pain, psychoaffective symptoms, and quality of life in human T cell lymphotropic virus type 1 (HTLV-1): a cross-sectional study. 61
33405200 2021
17
Decrease in naïve T cell production due to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development. 61
33338979 2021
18
Intrinsic and Extrinsic Cell Apoptotic Pathways in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Systematic Review. 61
33470891 2021
19
Therapeutic effects of virtual reality video gaming on functional mobility, balance, and gait speed in individuals with tropical spastic paraparesis: A randomized crossover clinical trial. 61
33533820 2021
20
Identification of dysregulated pathways underlying HTLV-1-associated myelopathy/tropical spastic paraparesis through co-expression network analysis. 61
33405203 2021
21
Spirituality as Strategies for Coping With Tropical Spastic Paraparesis: Results of Focus Group. 61
33417057 2021
22
Status of humoral and cellular immune markers in human T-cell lymphotropic virus type 1 (HTLV-1) asymptomatic carriers in northeastern Iran, Mashhad. 61
33025348 2020
23
Extracellular Vesicles in HTLV-1 Communication: The Story of an Invisible Messenger. 61
33322043 2020
24
The E3/E4 ubiquitin conjugation factor UBE4B interacts with and ubiquitinates the HTLV-1 Tax oncoprotein to promote NF-κB activation. 61
33362245 2020
25
Phylogenetic and phylodynamic study of Human T-cell lymphotropic virus Type 1 (HTLV-1) in Iran. 61
32561293 2020
26
Dietary Intake and Serum Selenium Levels Influence the Outcome of HTLV-1 Infection. 61
33169347 2020
27
Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis. 61
33161771 2020
28
Limitations in daily activities, risk awareness, social participation, and pain in patients with HTLV-1 using the SALSA and Participation scales. 61
32941806 2020
29
Effectiveness of virtual reality games for falls, postural oscillations, pain and quality of life of individual HAM/TSP: a randomized, controlled, clinical trial. 61
32737862 2020
30
Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: The impact of a neglected disease on the quality of life. 61
33064742 2020
31
Spasticity distribution and severity in individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
33021698 2020
32
Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
32705480 2020
33
HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina. 61
32883310 2020
34
The relative contributions of infectious and mitotic spread to HTLV-1 persistence. 61
32941445 2020
35
Regulation of Expression and Latency in BLV and HTLV. 61
32992917 2020
36
Cognitive impairment in the HTLV-1 infection: a comparative study associated with functional performance. 61
32955704 2020
37
A novel positive feedback-loop between the HTLV-1 oncoprotein Tax and NF-κB activity in T-cells. 61
32912211 2020
38
Neurologic, clinical, and immunologic features in a cohort of HTLV-1 carriers with high proviral loads. 61
32385802 2020
39
Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy. 61
32321893 2020
40
Molecular targeting of PD-1 signaling pathway as a novel therapeutic approach in HTLV-1 infection. 61
32283259 2020
41
Pilates exercise improves the clinical and immunological profiles of patients with human T-cell lymphotropic virus 1 associated myelopathy: A pilot study. 61
32825975 2020
42
Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
32620176 2020
43
Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
32667912 2020
44
Acupuncture in the treatment of HTLV-I-associated myelopathy / tropical spastic Paraparesis. 61
32350814 2020
45
Early-Onset HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. 61
32517313 2020
46
The IL-18, IL-12, and IFN-γ expression in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients, HTLV-1 carriers, and healthy subjects. 61
32270468 2020
47
Tropical spastic paraparesis in autochthon patient. 61
31784111 2020
48
Expression of TSLC1 in patients with HAM/TSP. 61
32285300 2020
49
Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient. 61
31930455 2020
50
Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques. 61
32576215 2020

Variations for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Expression for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Search GEO for disease gene expression data for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis.

Pathways for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Pathways related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.02 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
2
Show member pathways
12.83 IFNL3 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
3
Show member pathways
12.59 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
4
Show member pathways
12.45 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
5
Show member pathways
12.44 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
6 12.37 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
7
Show member pathways
12.05 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
8 11.91 VDR HLA-DRB1 HLA-DQB1
9 11.8 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
10
Show member pathways
11.47 HLA-DRB1 HLA-DQB1
11 11.44 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
12 11.38 HLA-DRB1 HLA-DQB1
13 11.1 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
14 10.89 HLA-B HLA-A

GO Terms for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

Cellular components related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.56 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
2 recycling endosome membrane GO:0055038 9.48 HLA-B HLA-A
3 phagocytic vesicle membrane GO:0030670 9.46 HLA-B HLA-A
4 endocytic vesicle membrane GO:0030666 9.43 HLA-DRB1 HLA-DQB1
5 transport vesicle membrane GO:0030658 9.4 HLA-DRB1 HLA-DQB1
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.37 HLA-DRB1 HLA-DQB1
7 MHC class II protein complex GO:0042613 9.32 HLA-DRB1 HLA-DQB1
8 ER to Golgi transport vesicle membrane GO:0012507 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
9 MHC class I protein complex GO:0042612 9.16 HLA-B HLA-A
10 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Biological processes related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.84 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
2 immune response GO:0006955 9.8 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
3 adaptive immune response GO:0002250 9.76 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
4 T cell receptor signaling pathway GO:0050852 9.7 HLA-DRB1 HLA-DQB1 HLA-A
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.57 HLA-B HLA-A
6 type I interferon signaling pathway GO:0060337 9.56 HLA-B HLA-A
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.55 HLA-B HLA-A
8 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.51 HLA-DRB1 HLA-DQB1
9 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.48 HLA-B HLA-A
10 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.43 HLA-B HLA-A
11 positive regulation of T cell mediated cytotoxicity GO:0001916 9.43 HLA-DRB1 HLA-B HLA-A
12 protection from natural killer cell mediated cytotoxicity GO:0042270 9.4 HLA-B HLA-A
13 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DRB1 HLA-DQB1
14 detection of bacterium GO:0016045 9.33 HLA-DRB1 HLA-B HLA-A
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.32 HLA-DRB1 HLA-DQB1
16 interferon-gamma-mediated signaling pathway GO:0060333 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
17 antigen processing and presentation GO:0019882 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Molecular functions related to Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.5 IFNL3 HLA-B HLA-A
2 T cell receptor binding GO:0042608 9.26 HLA-DRB1 HLA-A
3 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
4 TAP binding GO:0046977 8.96 HLA-B HLA-A
5 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Sources for Htlv-1 Associated Myelopathy/tropical Spastic Paraparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....